Cinacalcet(AMG-073) CAS 226256-56-0

Basic Info

Model No.: CAS 226256-56-0

Additional Info

Packaging: AS REQUIRED

Productivity: G,KGS,

Brand: VOLSENCHEM

Transportation: Air

Place of Origin: CHINA

Supply Ability: COMMERCIAL PRODUCTION

Certificate: GMP/ISO

Product Description

Our firm is competent to offer high purity Cinacalcet CAS 226256-56-0 to in present national and worldwide area. We have been engaged in this industry for many years so that we can offer pharmaceutical grade Cinacalcet CAS 226256-56-0 with competitive price. The Cinacalcet 226256-56-0 is known for high effective and reliable. Cinacalcet 226256-56-0 is indicated for the treatment of secondary hyperparathyroidism in people with chronic kidney disease on dialysis and hypercalcemia in people with parathyroid carcinoma. We have rich export experience, and can offer fast delivery.

• Thera. Category: Anti-Hyperparathyroidism
• Cas No.: 226256-56-0
• Synonym: CINACALCET;(aR)-α-Methyl-N-[3-[3-(trifluoromethyl)phenyl)propyl]-1-napthalenemethanamine;AMG 073;(aR)-a-Methyl-N-[3-[3-(trifluoromethyl)phenyl)propyl]-1-napthalenemethanamine;N-((1R)-1-(1-Naphthyl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amine;364782-34-3 (Hydrochloride);Cinacalcet [inn];Hsdb 7318
• Molecular Formula: C22H22F3N

• 
  
• Molecular Weight:357.41
• Specifications:Available on request
• Packing:Export worthy packing
• Material Safety Data Sheet:Available on request

Usage: Cinacalcet(AMG-073) is an orally active, second-generation calcimimetic compound; AMG 073 represents a new class of compounds for the treatment of hyperparathyroidism.Cinacalcet is the only calcimimetic approved for HPT secondary to chronic kidney disease (CDK), parathyroid carcinoma, and, in some countries, primary HPT. Clinical trials showed that cinacalcet reduced PTH and calcemia both in CDK and primary HPT, lowering the risk of bone fractures, surgery, and cardiovascular complications in the former patients. Long-term safety and pharmacoeconomics have to be fully tested yet. Few both in vitro and in vivo studies showed an association between Arg990Gly-CASR polymorphism and cinacalcet sensitivity, though in patients with severe CASR inactivating mutations the drug substantially retained its positive clinical effects.